JANX — Janux Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.84bn
- $810.04m
- $10.59m
- 51
- 20
- 20
- 21
Annual cashflow statement for Janux Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.78 | -32.7 | -63.1 | -58.3 | -69 |
| Depreciation | |||||
| Non-Cash Items | 0.278 | 6.74 | 15 | 12.3 | 22.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.12 | 8.84 | 4.28 | -6.55 | 0.685 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -4.37 | -17 | -42.9 | -50.6 | -43.8 |
| Capital Expenditures | 0 | -1.48 | -6.45 | -1.85 | -0.359 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -339 | 64.7 | -39.3 | -258 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -341 | 58.3 | -41.2 | -258 |
| Financing Cash Flow Items | 0 | 204 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.5 | 387 | 0.5 | 59.5 | 713 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.16 | 28.6 | 15.8 | -32.2 | 411 |